Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel Free VIRI Stock Alerts

Virios Therapeutics (VIRI) Competitors

Virios Therapeutics logo
$1.51 -0.09 (-5.63%)
As of 09/22/2026
Compare

VIRI vs. LENZ, VTVT, AARD, MIST, and VANI

Should you buy Virios Therapeutics stock or one of its competitors? Virios Therapeutics's main competitors and comparable companies include LENZ Therapeutics (LENZ), vTv Therapeutics (VTVT), Aardvark Therapeutics (AARD), Milestone Pharmaceuticals (MIST), and Vivani Medical (VANI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Virios Therapeutics compare to LENZ Therapeutics?

LENZ Therapeutics (NASDAQ:LENZ) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

In the previous week, LENZ Therapeutics had 4 more articles in the media than Virios Therapeutics. MarketBeat recorded 5 mentions for LENZ Therapeutics and 1 mentions for Virios Therapeutics. LENZ Therapeutics' average media sentiment score of 0.22 beat Virios Therapeutics' score of 0.00 indicating that LENZ Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
LENZ Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Virios Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

54.3% of LENZ Therapeutics shares are owned by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are owned by institutional investors. 8.3% of LENZ Therapeutics shares are owned by insiders. Comparatively, 12.2% of Virios Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

LENZ Therapeutics has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market. Comparatively, Virios Therapeutics has a beta of 1.58, suggesting that its stock price is 58% more volatile than the broader market.

Virios Therapeutics has a net margin of 0.00% compared to LENZ Therapeutics' net margin of -586.74%. LENZ Therapeutics' return on equity of -53.39% beat Virios Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
LENZ Therapeutics-586.74% -53.39% -49.14%
Virios Therapeutics N/A -130.33%-115.00%

LENZ Therapeutics currently has a consensus target price of $28.80, suggesting a potential upside of 670.26%. Given LENZ Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe LENZ Therapeutics is more favorable than Virios Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LENZ Therapeutics
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.50
Virios Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Virios Therapeutics has lower revenue, but higher earnings than LENZ Therapeutics. Virios Therapeutics is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LENZ Therapeutics$19.09M6.15-$82.13M-$4.09N/A
Virios TherapeuticsN/AN/A-$5.30M-$0.27N/A

Summary

LENZ Therapeutics beats Virios Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Virios Therapeutics compare to vTv Therapeutics?

vTv Therapeutics (NASDAQ:VTVT) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

vTv Therapeutics' return on equity of -6.27% beat Virios Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
vTv TherapeuticsN/A -6.27% -5.06%
Virios Therapeutics N/A -130.33%-115.00%

17.5% of vTv Therapeutics shares are held by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are held by institutional investors. 6.0% of vTv Therapeutics shares are held by company insiders. Comparatively, 12.2% of Virios Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Virios Therapeutics has lower revenue, but higher earnings than vTv Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than Virios Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
vTv Therapeutics$1.02M117.76-$26.97M-$1.06N/A
Virios TherapeuticsN/AN/A-$5.30M-$0.27N/A

In the previous week, vTv Therapeutics and vTv Therapeutics both had 1 articles in the media. vTv Therapeutics' average media sentiment score of 0.00 equaled Virios Therapeutics'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
vTv Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Virios Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

vTv Therapeutics presently has a consensus price target of $55.83, indicating a potential upside of 83.15%. Given vTv Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe vTv Therapeutics is more favorable than Virios Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
vTv Therapeutics
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.78
Virios Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

vTv Therapeutics has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market. Comparatively, Virios Therapeutics has a beta of 1.58, meaning that its stock price is 58% more volatile than the broader market.

Summary

vTv Therapeutics beats Virios Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Virios Therapeutics compare to Aardvark Therapeutics?

Aardvark Therapeutics (NASDAQ:AARD) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

Aardvark Therapeutics has a beta of 3.74, suggesting that its stock price is 274% more volatile than the broader market. Comparatively, Virios Therapeutics has a beta of 1.58, suggesting that its stock price is 58% more volatile than the broader market.

In the previous week, Aardvark Therapeutics had 20 more articles in the media than Virios Therapeutics. MarketBeat recorded 21 mentions for Aardvark Therapeutics and 1 mentions for Virios Therapeutics. Aardvark Therapeutics' average media sentiment score of 0.03 beat Virios Therapeutics' score of 0.00 indicating that Aardvark Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aardvark Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
20 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Virios Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

9.1% of Virios Therapeutics shares are owned by institutional investors. 17.8% of Aardvark Therapeutics shares are owned by insiders. Comparatively, 12.2% of Virios Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Aardvark Therapeutics currently has a consensus price target of $15.33, indicating a potential upside of 186.60%. Given Aardvark Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Aardvark Therapeutics is more favorable than Virios Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aardvark Therapeutics
2 Sell rating(s)
4 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.42
Virios Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Virios Therapeutics is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aardvark TherapeuticsN/AN/A-$57.59M-$3.21N/A
Virios TherapeuticsN/AN/A-$5.30M-$0.27N/A

Aardvark Therapeutics' return on equity of -71.54% beat Virios Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aardvark TherapeuticsN/A -71.54% -64.94%
Virios Therapeutics N/A -130.33%-115.00%

Summary

Aardvark Therapeutics beats Virios Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Virios Therapeutics compare to Milestone Pharmaceuticals?

Milestone Pharmaceuticals (NASDAQ:MIST) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

Milestone Pharmaceuticals has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market. Comparatively, Virios Therapeutics has a beta of 1.58, indicating that its stock price is 58% more volatile than the broader market.

Virios Therapeutics has lower revenue, but higher earnings than Milestone Pharmaceuticals. Virios Therapeutics is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Milestone Pharmaceuticals$2.34M45.64-$63.06M-$0.69N/A
Virios TherapeuticsN/AN/A-$5.30M-$0.27N/A

Milestone Pharmaceuticals presently has a consensus price target of $6.40, suggesting a potential upside of 645.05%. Given Milestone Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Milestone Pharmaceuticals is more favorable than Virios Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Milestone Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.71
Virios Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are owned by institutional investors. 5.0% of Milestone Pharmaceuticals shares are owned by company insiders. Comparatively, 12.2% of Virios Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Virios Therapeutics' return on equity of -130.33% beat Milestone Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Milestone PharmaceuticalsN/A -288.33% -58.27%
Virios Therapeutics N/A -130.33%-115.00%

In the previous week, Milestone Pharmaceuticals had 2 more articles in the media than Virios Therapeutics. MarketBeat recorded 3 mentions for Milestone Pharmaceuticals and 1 mentions for Virios Therapeutics. Milestone Pharmaceuticals' average media sentiment score of 0.67 beat Virios Therapeutics' score of 0.00 indicating that Milestone Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Milestone Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Virios Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Milestone Pharmaceuticals beats Virios Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Virios Therapeutics compare to Vivani Medical?

Virios Therapeutics (NASDAQ:VIRI) and Vivani Medical (NASDAQ:VANI) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

Virios Therapeutics is trading at a lower price-to-earnings ratio than Vivani Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virios TherapeuticsN/AN/A-$5.30M-$0.27N/A
Vivani MedicalN/AN/A-$26.61M-$0.35N/A

Vivani Medical has a consensus price target of $3.75, suggesting a potential upside of 207.38%. Given Vivani Medical's stronger consensus rating and higher probable upside, analysts plainly believe Vivani Medical is more favorable than Virios Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Virios Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Vivani Medical
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

In the previous week, Virios Therapeutics had 1 more articles in the media than Vivani Medical. MarketBeat recorded 1 mentions for Virios Therapeutics and 0 mentions for Vivani Medical. Virios Therapeutics' average media sentiment score of 0.00 equaled Vivani Medical'saverage media sentiment score.

Company Overall Sentiment
Virios Therapeutics Neutral
Vivani Medical Neutral

Virios Therapeutics' return on equity of -130.33% beat Vivani Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Virios TherapeuticsN/A -130.33% -115.00%
Vivani Medical N/A -191.05%-70.91%

9.1% of Virios Therapeutics shares are held by institutional investors. Comparatively, 6.8% of Vivani Medical shares are held by institutional investors. 12.2% of Virios Therapeutics shares are held by insiders. Comparatively, 53.3% of Vivani Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Virios Therapeutics has a beta of 1.58, suggesting that its stock price is 58% more volatile than the broader market. Comparatively, Vivani Medical has a beta of 2.36, suggesting that its stock price is 136% more volatile than the broader market.

Summary

Vivani Medical beats Virios Therapeutics on 7 of the 12 factors compared between the two stocks.

Get Virios Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for VIRI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VIRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VIRI vs. The Competition

Export
MetricVirios TherapeuticsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$29.08M$12.59B$7.31B$13.28B
Dividend YieldN/A2.63%2.52%12.56%
P/E Ratio-5.59792.28274.0725.70
Price / SalesN/A857.34673.2290.62
Price / CashN/A88.6477.8052.76
Price / Book7.5510.5810.386.32
Net Income-$5.30M$2.81B$3.49B$359.73M
7 Day Performance-11.18%-0.16%-0.69%0.17%
1 Month Performance-39.36%-1.38%-3.19%-3.27%
1 Year Performance-70.00%2.83%15.12%5.58%

Virios Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VIRI
Virios Therapeutics
N/A$1.51
-5.6%		N/A-70.8%$29.08MN/AN/A5
LENZ
LENZ Therapeutics
3.1478 of 5 stars		$4.23
-5.4%		$28.80
+580.9%		-90.7%$140.45M$19.09MN/A152
VTVT
vTv Therapeutics
2.6625 of 5 stars		$30.46
-3.1%		$55.83
+83.3%		+36.2%$123.84M$1.02MN/A26
AARD
Aardvark Therapeutics
3.4537 of 5 stars		$5.02
-9.5%		$15.33
+205.4%		-51.4%$121.46MN/AN/A28
MIST
Milestone Pharmaceuticals
2.4601 of 5 stars		$0.93
-2.3%		$6.40
+589.9%		-55.3%$118.20M$1.55MN/A38

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:VIRI) was last updated on 9/24/2026 by MarketBeat.com Staff.
From Our Partners
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
How to get a stake in Anthropic — before the IPO
Anthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...
Weiss Ratings | Sponsoredtc pixel
Why I believe the AI market will split in Q4
Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...
The Oxford Club | Sponsoredtc pixel
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...
Digest Publishing | Sponsoredtc pixel
Congress Passes Landmark Digital Asset Law Wall Street Is Watching
The House passed the Digital Asset Market Clarity Act 294 to 134, creating the most comprehensive financial te...
Awesomely | Sponsoredtc pixel
If you keep cash in a U.S. bank account… read this NOW
Since 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...
Banyan Hill Publishing | Sponsoredtc pixel
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
He turned $12K into $1.65M without touching Apple or Tesla
Tim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...
Tim Sykes | Sponsoredtc pixel